Free Trial

Northern Trust Corp Makes New $2.66 Million Investment in CeriBell (NASDAQ:CBLL)

CeriBell logo with Medical background

Northern Trust Corp bought a new stake in CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 102,828 shares of the company's stock, valued at approximately $2,661,000. Northern Trust Corp owned about 0.29% of CeriBell at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of CBLL. Rhumbline Advisers purchased a new position in CeriBell during the fourth quarter worth about $320,000. Corebridge Financial Inc. acquired a new position in CeriBell during the 4th quarter worth approximately $158,000. PNC Financial Services Group Inc. purchased a new position in shares of CeriBell during the 4th quarter worth approximately $47,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of CeriBell in the 4th quarter valued at approximately $10,750,000. Finally, Vanguard Group Inc. purchased a new stake in shares of CeriBell in the fourth quarter valued at approximately $18,015,000.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $16.96, for a total value of $424,000.00. Following the sale, the chief executive officer now owns 727,151 shares of the company's stock, valued at $12,332,480.96. This represents a 3.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 49,700 shares of company stock worth $796,434. 20.10% of the stock is owned by corporate insiders.

CeriBell Stock Performance

Shares of CBLL traded up $0.70 on Tuesday, reaching $17.28. The stock had a trading volume of 628,500 shares, compared to its average volume of 279,409. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75. The firm has a 50-day moving average of $17.06 and a 200 day moving average of $21.98.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.49 million during the quarter, compared to analysts' expectations of $19.30 million. As a group, equities analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $32.50.

View Our Latest Report on CBLL

CeriBell Profile

(Free Report)

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

Featured Stories

Institutional Ownership by Quarter for CeriBell (NASDAQ:CBLL)

Should You Invest $1,000 in CeriBell Right Now?

Before you consider CeriBell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.

While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines